Show simple item record

dc.contributor.authorFunck-Brentano, Christian
dc.contributor.authorNguyen, Lee S.
dc.contributor.authorSalem, Joe-Elie
dc.date.accessioned2020-08-10T13:28:16Z
dc.date.available2020-08-10T13:28:16Z
dc.date.issued2020-07-09
dc.identifier.urihttps://doi.org/10.1016/S0140-6736(20)31528-2en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12663/2112
dc.description.abstractA recent Lancet Article by Mandeep Mehra and colleagues, which reported adverse events associated with hydroxychloroquine or chloroquine treatment in patients with COVID-19, has been retracted by three of the authors, along with our linked Comment that provided a commentary on the Article and its findings, because the veracity of the data underlying this observational study could not be assured by the study authors. Subsequently, an article that used data from the same Surgisphere database, and which was authored by some of the same individuals, was retracted from the New England Journal of Medicine. Nevertheless, the debate about hydroxychloroquine for COVID-19 continues. Here, we provide a discussion of what is currently known about its proven and potential harms. Hydroxychloroquine is a 4-aminoquinoline that prolongs ventricular repolarisation, as evidenced by prolongation of the QT interval corrected for heart rate (QTc) on the electrocardiogram. QTc prolongation can be associated with a specific ventricular arrhythmia called torsade de pointes, which, although often self-terminating, can degenerate into ventricular tachycardia or fibrillation, leading to death. Torsade de pointes is a rare event, with an estimated annual crude rate of 3·2 per million population; the incidence is almost doubled in women compared with men and increases with age. Drug-induced torsade de pointes mostly occurs by blockade of the cardiac rapid delayed rectifier channels in the presence of several risk factors, including high drug concentration, simultaneous exposure to multiple QTc-prolonging drugs, coronary heart disease, heart failure, hypokalaemia, bradycardia, or congenital long-QT syndrome, among others.en_US
dc.languageEnglishen_US
dc.subjectCOVID-19en_US
dc.subjectCoronavirus Infectionsen_US
dc.subjectInfectious Diseasesen_US
dc.subjectCardiotoxicityen_US
dc.subjectHydroxychloroquineen_US
dc.titleRetraction and republication: cardiac toxicity of hydroxychloroquine in COVID-19en_US
eihealth.countryOthersen_US
eihealth.categoryEthical considerations for researchen_US
eihealth.typePublished Articleen_US
eihealth.maincategorySave Lives / Salvar Vidasen_US
dc.relation.ispartofjournalThe Lanceten_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record